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Background: Using high-resolution ultrasonography (US) to measure the median nerve cross-sectional areas (CSAs)
such as in the “inching test” conducted in nerve conduction studies is a valuable tool to assess carpal tunnel
syndrome (CTS). However, using this US measurement method to assess the median nerve CSA in diabetic patients
with CTS has rarely been reported. Therefore, we used this US measurement method in this study to measure
median nerve CSAs and to compare the CSAs of idiopathic, diabetic and diabetic polyneuropathy (DPN) patients
with CTS.
Methods: 124 hands belonging to 89 participants were included and assigned into four groups: control (32),
idiopathic (38), diabetic (38) and DPN (16) CTS. In the latter two groups, only patients with mild and moderately
severe CTS were included. The median nerve CSAs were measured at 8 points marked as i4, i3, i2, i1, w, o1, o2, and
o3 in the inching test. The measured CSAs in each group of participants were compared.
Results: Compared with the CSAs of the control group, enlarged CSAs were found in the idiopathic, diabetic and
DPN CTS groups. The CSAs were larger at i4, i3 and i2 in the diabetic CTS group compared to the idiopathic CTS
group. The CSAs measured at the i1 and w levels of the DPN CTS group were smaller than those of the diabetic
CTS group. In the diabetic CTS group, the cut-off values of CSAs measured at the inlet, wrist crease, and outlet were
15.3 mm2, 13.4 mm2 and 10.0 mm2, respectively, and 14.0 mm2, 12.5 mm2 and 10.5 mm2, respectively, in the DPN
CTS group.
Conclusions: Compared with the median nerve CSAs of the control and idiopathic CTS groups, the median nerve
CSAs of the diabetic patients with CTS were significantly enlarged. However, compared with the diabetic CTS
group, the CSAs were significantly smaller in the DPN CTS group. This US 8-point measurement method can be of
value as an important complementary tool for CTS studies and diagnosis among diabetic patients.* Correspondence: cwenneng@ms19.hinet.net
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Carpal tunnel syndrome (CTS) is a common entrapment
neuropathy with prevalence rates of 2% in the general
population, 14% in diabetic patients without diabetic
polyneuropathy (DPN), and 30% in diabetic patients
with DPN [1,2]. The diagnosis of CTS is usually based
on clinical symptoms as well as the results of nerve con-
duction studies (NCS). However, because of diabetic
hand syndromes, the diagnosis of CTS in patients with
diabetes can be difficult if using clinical symptoms and
NCS with various comparative tests [3-7] alone. Ultra-
sonography (US) is a non-invasive and easily performed
procedure for median nerve morphology measurement.
Based on the findings of median nerve cross-sectional
area (CSA) enlargement in the carpal tunnel, US can
be used to confirm CTS with a high degree of accuracy
[8-10]. US has been used in clinical studies on diabetic
neuropathy [11,12], however its use in the clinical evalu-
ation of CTS in diabetic patients has not been reported
in the literature. In our previous study, we reported the
results of an US study [10] for the evaluation of idio-
pathic CTS using the same 8-point measurements of the
median nerve CSAs from inlet to outlet as in the
“inching test” of antidromic sensory studies using 1-cm
increments of the median nerve [13]. Although there
were some limitations to the study, the results showed
the value of this US measurement method as an import-
ant complementary tool to confirm CTS. Therefore we
used this US measurement method in this study to
measure median nerve CSAs, and to compare the mea-




This prospective case–control study was carried out over
a period of four years (2006–2009), and was approved by
the Ethics Committee of Chang Gung Memorial Hos-
pital (IRB 100-1390B). In this study, the following proce-
dures were used to enroll the study cases: first, those
who had signs and symptoms fulfilling the clinical diag-
nostic criteria of CTS were referred by the authors to
undergo NCS and US studies; then, those who fulfilled
the inclusion criteria of idiopathic CTS, diabetic CTS or
DPN CTS were further considered for enrollment, and
finally, those who agreed to sign informed consent forms
were enrolled into this study. Normal controls were also
recruited.
In this study, diabetic patients were defined as those
who had symptoms (polyuria, polydipsia, and unex-
plained weight loss) of diabetes mellitus (DM) plus a
casual plasma glucose concentration ≥ 200 mg/dL, or a
fasting plasma glucose level of ≥ 126 mg/dL on at least
two occasions, or a plasma glucose level of ≥ 200 mg/dLat two hours for a 75-g oral glucose tolerance test
(OGTT) [14]. In the control and idiopathic CTS groups,
DM was excluded by a fasting serum glucose
level< 100 mg/dl, or a two-hour postprandial serum
glucose level< 110 mg/dl and no clinical symptoms of
DM. Serum glycohemoglobin (HbA1C) levels of all en-
rolled participants were measured. Patients with other
systemic diseases including gout, rheumatic arthritis,
thyroid disease, renal disease, hepatic disease, abnormal
serum cortisol levels or elevated serum antinuclear anti-
bodies were excluded by blood tests and clinical history.
None of the participants had a history of wrist surgery
or fracture, and none had a history or any clinical evi-
dence of neurologic disorders (e.g. ulnar neuropathy,
radiculopathy, polyneuropathy (not DM related), myel-
opathy, or stroke) that may have resulted in numbness
or paresthesia of the hand. Participants with a variant of
carpal tunnel such as accessory muscles, bifid median
nerve and persistent median artery found by US were
also excluded. In addition, none of the female partici-
pants were pregnant at the time of the study.
Definition of clinical CTS
Clinical CTS was defined according to the criteria of
The American Academy of Neurology practice para-
meters [15,16] as follows:
1. Paresthesia, pain, swelling, weakness, or clumsiness
of the hand provoked or worsened by sleep,
sustained hand or arm position, or repetitive action
of the hand or wrist that is mitigated by changing
posture or by hand shaking.
2. Sensory deficits in the median nerve innervated
region of the hand.
3. Motor deficit or hypotrophy of the median nerve
innervated thenar muscles.
4. Positive provocative clinical tests (positive Phalen’s
maneuver and/or Tinel’s sign).
Clinical CTS was defined as the fulfillment of criterion
1 and one or more of the other criteria.
Clinical definition of polyneuropathy
The symptoms and signs of suspected DPN were exam-
ined according to the recommendations of the American
Academy of Electrodiagnostic Medicine (AAEM) [17]. A
combination of neuropathic symptoms, neuropathic
signs and abnormal electrodiagnostic studies provides
the diagnosis of distal symmetric polyneuropathy. In this
study, an electrodiagnostic abnormality plus at least one
sign and one symptom were sine qua non for the con-
firmation of the presence of polyneuropathy. The neuro-
pathic symptoms included sensory symptoms (distal
numbness, burning, prickling paresthesia, dysesthesia
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ibility on the distal lower extremity, distal muscle weak-
ness or atrophy). The neuropathic signs included an
absent or decreased ankle deep tendon reflex, distal sen-
sory decrease or absence, and distal weakness and
muscle atrophy. Abnormal electrodiagnostic studies
included at least a sural, or peroneal and one median or
ulnar nerve dysfunction, however entrapment lesions
were excluded
Electrophysiologic methods
NCS was performed for all participants according to the
recommended protocol of the AAEM [18] using a Nico-
let Viking Select system (Nicolet Biomedical Inc. Madi-
son, USA). The comparative tests and the cut-off points
were as follows [19-23]: 1) median-ulnar sensory con-
duction between the wrist and ring finger; 2) median
sensory nerve conduction comparison between the wrist
and palm; 3) median-radial sensory conduction between
the wrist and thumb; and 4) antidromic sensory test
using 1-cm increments of the median nerve; 5) median
nerve distal sensory latency< 3.4 ms; 6) median nerve
distal motor latency over the thenar< 4.2 ms; 7) a differ-
ence between the median and ulnar nerve distal sensory
latencies< 0.4 ms; 8) transcarpal median motor conduc-
tion velocity< 40.6 ms; and 9) antidromic sensory test-
ing using 1-cm increments of the median
nerve< 0.4 ms. The locations of the inching test were as
shown in Figure 1, with the wrist crease as the zero
reference point extending proximally by 3 cm and dis-
tally by 4 cm. In total, eight points (i4, i3, i2, i1, w, o1,
02, 03) were marked in the subsequent inching test.
According to the results of the NCS, the CTS handsFigure 1 The 8 points (i4, i3, i2, i1, w, o1, o2, and o3) for
recording in both the “inching test” and ultrasonography. i4, i3,
i2, i1 represent levels at 4, 3, 2, and 1 cm distal to the wrist crease in
the inlet of the carpal tunnel; w represents the level of the wrist
crease and o1, o2, and o3 represent levels at 1, 2, and 3 cm proximal
to the wrist crease in the outlet of the carpal tunnel.were categorized into six groups of severity [23]: nega-
tive, minimal, mild, moderate, severe and extreme. In
this study, only those belonging to the mild (abnormal
digit/wrist sensory nerve conduction velocity and nor-
mal distal motor latency) and moderate (abnormal digit/
wrist sensory nerve conduction velocity and abnormal
distal motor latency) NCS groups were included in the
final analysis.
NCS for polyneuropathy detection was also performed
according to the study protocol of the AAEM [17].
Sural, tibial, ulnar and peroneal nerves were also exam-
ined to determine whether or not the included partici-
pants fit the diagnostic criteria of polyneuropathy. The
segmental tests (ulnar nerve at elbow and peroneal
nerve at the fibula head) were also performed to exclude
entrapment neuropathy.
The normal limits of NCS of the abovementioned nerves
other than the median nerve were as follows: ulnar nerve
(distal motor latency< 3.4 ms, motor conduction
velocity> 52 m/s, sensory conduction velocity> 44 m/s,
compound muscle action potential> 5.5 mV, sensory nerve
action potential> 9 μV), peroneal (distal latency< 5.5 ms,
conduction velocity> 42 m/s, compound motor action
potential> 2.1 mV), tibial nerve (distal latency< 6.4 ms,
conduction velocity> 41 m/s, compound motor action
potential> 4.7 mV), and sural nerve (conduction
velocity> 38 m/s, sensory nerve action potential> 5 μV).Ultrasound assessment technique
The US assessment technique we used in this study has
been previously described [10]. In brief, high-resolution
US were performed using a scanner with a 12/5-MHz
linear array transducer for the carpal tunnel study (Phi-
lips HDI 5000; Philips Medical Systems, Bothell, WA,
USA). US examinations were performed on the same
day as the NCS. During the examination, the patient sat
in a comfortable position facing the examiner, with the
measured forearm resting on the table, the palm supine,
and fingers semi-extended in the neutral position [24].
The median nerve was imaged in a longitudinal scan
first, placing the US probe at the midline between the
radius and ulna with the center of the probe at the distal
wrist crease, to obtain an initial general overview of the
median nerve which was then used to assist the exam-
iner in order to obtain optimal axial (cross-sectional)
images. Then a transverse scan, keeping the probe dir-
ectly perpendicular to the long axis of the median nerve
in order to ensure that the area measured indeed
reflected a CSA, was performed to record the CSA (cal-
culated by continual tracing of the nerve circumference,
excluding the hyperechoic epineurial rim) and elliptical
(the transverse and the anteroposterior) diameters. The
measurements were performed from the inlet of carpal
Table 1 Demographic data of the 89 participants (124 hands)
Control hands Idiopathic CTS hands Diabetic CTS hands DPN CTS hands p value
Numbers 32 38 38 16
Sex 9 M/23 F 9 M/29 F 9 M/29 F 4 M/12 F 0.971+
Age (yrs) 56.5 ± 8.0 (54.5, 48.0-76.0) 59.2 ± 9.3 (57.0, 44.0-83.0) 58.6 ± 9.4 (56.0, 38.0-76.0) 61.0 ± 7.8 (63.0, 50.0-73.0) 0.365
BH (cm) 160.6 ± 8.6 (159.0, 151.0-184.0) 157.0 ± 5.1 (157.0, 147.0-167.0)※ 155.3 ± 5.3 (154.0, 146.0-170.0) 151.7 ± 4.8 (150.0, 143.0-160.0) 0.002*
BW (kg) 61.8 ± 9.6 (60.0, 51.3-96.0) 63.3 ± 9.5 (62.0, 47.0-82.0) 68.0 ± 12.0 (67.0, 45.0-92.0) 61.6 ± 10.9 (60.0, 50.0-88.0) 0.099
BMI kg/m2 23.9 ± 2.3 (24.2, 19.7-28.4) 25.6 ± 3.2 (24.9, 20.3-31.6) 28.0 ± 4.5 (27.2, 19.7-35.9) 26.8 ± 4.8 (25.6, 21.4-39.1) 0.002*
HbA1c (%) 5.6 ± 0.4 (5.6, 5.0-6.2) 5.8 ± 0.3 (5.8, 5.3-6.3) 7.3 ± 1.0 (7.2, 5.7-9.5) 7.9 ± 3.0 (6.9, 6.1-18.9) 0.904
CTS = carpal tunnel syndrome; DPN=diabetic polyneuropathy; BH =body height; BW=body weight; BMI = body mass index; M=male; F = female.
The data shown are mean ± standard deviation (SD) (median, range).
*= p< 0.05 (significant difference among the normal control, idiopathic, diabetic and DPN CTS hands) by the Kruskal-Wallis test.
+ = a comparison of the sex difference and symptom duration among the control, idiopathic, diabetic and DPN CTS hands by the Chi-Square test.




















Table 2 The measured CSAs of the control, idiopathic, diabetic and DPN groups
Control hands (n = 32) Idiopathic CTS hands (n = 38) Diabetic CTS hands (n = 38) DPN CTS hands (n = 16) p value1 p value2 p value3
i4 12.6 ± 3.0 (12.0, 6.0-19.0) 17.5 ± 6.4 (16.5, 8.0-39.0) 20.4 ± 5.4 (19.5, 13.0-34.0) 20.9 ± 13.8(15.5, 8.4-62.0) 0.015* 0.109 0.000*
i3 12.2 ± 2.9 (12.0, 6.0-19.0) 16.3 ± 5.8 (15.5, 8.0-33.0) 19.3 ± 5.5 (19.0, 10.0-31.0) 19.0 ± 9.1 (15.5, 8.4-43.0) 0.015* 0.310 0.000*
i2 11.5 ± 2.5 (11.0, 7.0-18.0) 12.5 ± 3.7 (12.0, 6.0-29.0) 14.2 ± 3.9 (13.5, 9.0-24.0) 13.6 ± 5.9 (11.5, 9.0-34.0) 0.026* 0.242 0.010*
i1 10.8 ± 2.1 (10.2, 7.0-17.0) 14.0 ± 4.8 (13.0, 8.0-28.0) 15.5 ± 4.4 (14.8, 7.7-26.1) 12.7 ± 3.1 (13.0, 7.0-21.0) 0.105 0.043* 0.000*
w 11.8 ± 2.6 (11.0, 8.0-19.0) 16.2 ± 4.5 (15.0,11.0-31.0) 17.9 ± 6.6 (16.0, 8.1-45.8) 14.8 ± 4.7 (13.5, 8.0-28.0) 0.217 0.039* 0.000*
o1 10.6 ± 2.4 (10.0, 6.0-16.0) 14.0 ± 3.7 (13.4, 8.0-23.0) 15.4 ± 5.9 (14.0, 7.0-42.8) 14.3 ± 5.5 (13.0, 7.0-30.0) 0.237 0.458 0.000*
o2 11.0 ± 2.6 (10.5, 7.0-17.0) 12.2 ± 2.6 (12.0, 8.0-19.5) 13.8 ± 4.0 (13.0, 8.6-29.0) 12.8 ± 5.3 (12.5, 7.4-29.0) 0.090 0.181 0.006*
o3 10.0 ± 2.4 (9.5, 7.0-15.0) 10.8 ± 2.2 (10.4, 6.0-16.0) 12.4 ± 3.5 (11.7, 7.0-20.0) 12.2 ± 4.0 (10.5, 8.7-25.0) 0.060 0.601 0.017*
CTS = carpal tunnel syndrome; CSA = cross-sectional area; DPN=diabetic polyneuropathy.
The data shown are mean ± standard deviation (SD) (median, range).
Unit of CSA=mm2.
i4, i3, i2, i1, w, o1, o2, and o3= the 8 points marked.
p value1 = a comparison between the idiopathic and the diabetic CTS hands using the Mann–Whitney U test.
p value2 = a comparison between the diabetic and the DPN CTS hands using the Mann–Whitney U test.
p value3 = a comparison among control, idiopathic CTS, the diabetic and the DPN CTS hands using the Kruskal-Wallis test.




















Table 3 The cut-off values of CSA of the idiopathic, diabetic and DPN CTS groups (compared with the control group)
Location Idiopathic CTS group Diabetic CTS group DPN CTS group
Sen. Spec. Area Cuff-off value of CSA Sig. Sen. Spec. Area Cuff-off value of CSA Sig. Sen. Spec. Area Cuff-off value of CSA Sig.
i4 73.7 59.4 0.760 13.0 0.000* 84.2 84.4 0.921 15.3 0.000* 62.5 59.4 0.750 14.0 0.005*
i3 73.7 62.5 0.734 12.8 0.001* 76.3 93.7 0.889 15.3 0.000* 62.5 68.7 0.784 14.0 0.001*
i2 63.2 62.5 0.602 11.4 0.142 63.2 71.9 0.722 12.4 0.001* 50.0 62.5 0.620 11.5 0.179
i1 71.1 62.5 0.727 11.5 0.001* 76.3 62.5 0.813 11.4 0.000* 62.5 62.5 0.716 11.5 0.016*
w 78.9 68.7 0.824 12.5 0.000* 81.6 71.9 0.859 13.4 0.000* 62.5 68.7 0.731 12.5 0.010*
o1 68.4 65.6 0.777 11.5 0.000* 81.6 65.6 0.832 11.2 0.000* 75.0 65.6 0.757 11.7 0.004*
o2 60.5 65.6 0.647 11.5 0.035* 76.3 65.6 0.744 11.0 0.000* 56.3 65.6 0.600 11.5 0.265
o3 73.7 50.0 0.598 9.5 0.159 68.4 56.2 0.698 10.0 0.004* 50.0 56.2 0.688 10.5 0.035*
CSAs = cross-sectional areas; DPN=diabetic polyneuropathy; Sen. =sensitivity; Spec. =specificity; Sig. =significance; ROC= Receiver Operating Characteristic; CTS = carpal tunnel syndrome; NCS = nerve conduction study.
i4, i3, i2, i1, w, o1, o2, and o3= the 8 points marked.
Unit of CSA=mm2; Sen. = %; Spec. = %.
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Figure 1, at the 8 points (i4, i3, i2, i1, w, o1, 02, 03) [10].
Study patient groups
In total, 124 hands belonging to 89 participants were en-
rolled in this study, and they were divided into four
groups as follows:
1. Control group (22 participants, 32 hands):
Healthy volunteers who had no clinical or
electrophysiologic evidence of CTS or other
neurologic disorders.
2. Idiopathic CTS group (30 participants, 38 hands):
Those who had clinical and electrophysiologic
evidence of CTS, but no other medical or neurologic
disorders that may have resulted in numbness or
paresthesia of the hands.
3. Diabetic CTS group (26 participants, 38 hands):
Those who had clinical symptoms and findings of
CTS, and also fulfilled the electrophysiologic criteria
of CTS. They did not have clinical or
electrophysiologic evidence of polyneuropathy, ulnar
or radial neuropathy.
4. DPN CTS group (11 participants, 16 hands):
Diabetic patients who had clinical symptoms and
findings of CTS and also fulfilled the
electrophysiologic criteria of CTS. They also had
clinical and electrophysiologic evidence of
polyneuropathy.
Among the enrolled CTS patients, bilateral hand in-
volvement was noted in 11 patients of the idiopathic
CTS group, 7 in the diabetic CTS group and 3 in the
DPN CTS group.
Statistical analysis
The data were all presented as mean± standard devi-
ation (median, range) for statistical analysis. Compari-
sons between the demographic data of the control,
idiopathic, diabetic CTS and DPN CTS groups were
made using the Kruskal-Wallis test for continuous vari-
ables including age, body weight (BW), body height
(BH), body mass index (BMI). The chi-square test was
used for the categorical variables including sex. To
evaluate the differences in CSA values measured at the 8
points between the idiopathic, diabetic and DPN CTS
hands, the Mann–Whitney U test was used. Significance
was set at p< 0.05 in the Mann–Whitney U test and
Kruskal-Wallis test. The area under the receiver operat-
ing characteristic (ROC) curves and the cut-off-values of
CSA were calculated for the idiopathic, diabetic and
DPN CTS groups. The Statistical Package for Social
Sciences software (SPSS Inc., version 13.0 for Windows)
was used for all statistical analyses.Results
The demographic data of the 89 participants (142 hands)
are shown in Table 1. There were no significant differ-
ences in age, gender and BW among the control, idio-
pathic, diabetic and DPN CTS groups. Compared with
the control group, the BH was shorter in the diabetic
and DPN CTS groups; however the BMI was higher in
the idiopathic, diabetic and DPN CTS groups. If the
control group was not included for analysis, differences
in MBI values among the idiopathic, diabetic and DPN
CTS groups were not significant (p= 0.165). There were
no significant differences in HbA1c values between the
diabetic and DPN CTS groups.
The CSAs measured at the 8 points (i4, i3, i2, i1, w,
o1, o2, o3) of the four groups of participants are listed in
Table 2. The measured CSAs were larger at i4, i3 and i2
of the diabetic group than those of the idiopathic CTS
group. Compared with the diabetic group, the CSAs
measured at the i1 and w levels of the DPN group were
smaller.
Table 3 and Figure 2 show the cut-off values and cor-
responding sensitivities and specificities of CSAs in the
diagnosis of CTS in the idiopathic, diabetic and DPN
groups. These cut-off values were derived from a com-
parison with the CSAs of the control group. In the idio-
pathic group, the cut-off values of CSAs measured at the
inlet, wrist crease, and outlet were 13.0 mm2, 12.5 mm2
and 9.5 mm2, respectively; in the diabetic group
15.3 mm2, 13.4 mm2 and 10.0 mm2, respectively; and
14.0 mm2, 12.5 mm2 and 10.5 mm2, respectively, in the
DPN group. The largest CSA cut-off value at the w level
was in the diabetic group. At the outlet levels, there
were no significant differences in cut-off values between
the control and the idiopathic group, however there
were statistically significant differences between the con-
trol (CSA cut-off value = 9.5 mm2) and diabetic group
(CSA cut-off value = 10.0 mm2), and between the control
and the DPN group (CSA cut-off value = 10.5 mm2).
Discussion
In clinical practice, it is difficult to distinguish CTS from
other neuropathic syndromes in diabetic patients, even
when electrodiagnostic tests are also applied for such
purposes [2,5,6]. An enlargement of median nerve CSA
measured in CTS hands is a well established US finding
[8-10], and with multiple-level CSA measurements, the
complementary role of US in the diagnosis of CTS
becomes more valuable [10]. The same US findings were
also noted in the present study which showed enlarged
CSAs in patients with idiopathic CTS as well as in those
with diabetic CTS and DPN CTS. There are reports
[11,12] of US studies of peripheral nerves in diabetic
patients, however using US to measure the CSAs at 8
AB
C
Figure 2 ROC curves of the cut-off values of cross-sectional
areas (CSA) of the idiopathic (A), diabetic (B) and diabetic
polyneuropathy (DPN) (C) carpal tunnel syndrome (C).
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betic patients has not been reported before.
The study results showed that the measured CSAs in
both the diabetic and DPN groups were larger than
those measured in the idiopathic and control groups.
The BMIs of patients of the CTS groups were signifi-
cantly larger than those of patients in the control group.
It has been proposed that a higher BMI may increase
the incidence of symptomatic CTS [3], however a signifi-
cant correlation with median nerve CSA measured at
the wrist level was not found in the study of Werner
et al. [25]. It may deserve further investigations to dem-
onstrate if a correlation exists between BMI and CSA in
diabetic patients with CTS. BH was another statistically
significant factor between the different groups. It has
been proposed that a difference in BH may influence
the result of nerve conduction velocity [26], however it
is not a known factor to influence the median nerve
CSA [27].
In US studies, different CSA cut-off values (9 mm2 –
14 mm2) at the entry level (inlet) of the carpal tunnel
have been reported for CTS confirmation in idiopathic
CTS patients [28]. In the present study, we revealed the
cut-off values of CSAs measured at different levels of
the patients with idiopathic, diabetic and DPN CTS. Al-
though larger CSAs measured in the carpal tunnel 5 cm
proximal to the wrist and elbow joint of the median
nerve in diabetic and diabetic polyneuropathy patients
were reported by Watanabe et al. [11,12], comparative
results of measured CSAs at the inlet level of diabetic
patients have not been reported before. In the present
study, we measured the CSAs within the carpal tunnel
in the hands of the diabetic patients with CTS, and the
results also showed larger CSAs when compared with
the CSAs measured in both the control and idiopathic
groups. Several factors are known to be contributing fac-
tors to CTS, including mechanical and ischemic factors,
external epineurial and perineurial thickening and fibro-
sis [29], and all of these factors may in-part explain the
local enlargement of median nerve CSAs. However, as
shown in this study, there may be additional factors con-
tributing to the focal enlargement of median nerve CSAs
in diabetic patients, and especially at the level of the in-
let. In DM, the polyol pathway, glycation and proinflam-
matory reactions are known to contribute to the
presence of diabetic peripheral nerve injuries [30], and a
reduction in myelinated nerve fibers and capillary dens-
ity may predispose DM patients to the development of
CTS [31]. In addition, more ischemic and biochemical
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nerve CSAs.
One peculiar finding of the present study is that the
measured median nerve CSAs of the patients in the
DPN group, especially at i1 and w levels, were smaller
than those measured in the diabetic group. This finding
has not been reported previously, but may be partially
related to the loss of nerve regeneration capacity in
advanced diabetic neuropathy [4,31,32]. This finding
may also partially explain why the response to CTS
treatment in diabetic patients varies greatly, especially
when different intervention methods are used, when
compared with the therapeutic results of idiopathic CTS
[33-35].
There are limitations to this study. First, some of the
patients may have been included twice if they had bilat-
eral CTS symptoms. Second, the number of cases is lim-
ited; therefore, US findings in the different subgroups of
CTS patients could not be fully analyzed. Further large-
scale studies of US findings in CTS among diabetic
patients are needed for a better delineation.Conclusion
This is the first study to use US and an 8-point measure-
ment method to assess and compare the median nerve
CSAs of participants belonging to control, idiopathic,
diabetic and DPN CTS groups. We suggest the cut-off
values for CTS confirmation in each group, and also
show the following: 1) Compared with the controls, the
CSAs were significantly enlarged in patients with idio-
pathic CTS, diabetic CTS and DPN CTS; 2) Compared
with the idiopathic group, the CSAs were significantly
enlarged in patients with diabetic CTS and DPN CTS;
and 3) Compared with the diabetic group, the CSAs
were significantly smaller in patients in the DPN group.
Several pathophysiologic mechanisms may, at least par-
tially, explain the findings of the inter-group differences
of median nerve CSAs. This US 8-point measurement
method can be of value as an important complementary
tool for the diagnosis of CTS among diabetic patients.
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